GH Research (NASDAQ:GHRS) Stock, Quote.Headers.trade-ideas

GH Research

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

ibrahim-rifath-OApHds2yEGQ-unsplash(3)

Cannabis

Earnings

News

Psychedelics

GHRS

Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and marketable securities were $204.5 million as of June 30, 2024, compared to cash, cash equivalents, other financial assets and marketable securities of $222.7 million as of December 31, 2023.The net loss was $10.4 million, or $0.20 loss per share, for the quarter that ended June 30, 2024, compared to the $7.7 million or $0.15 loss per share for the same quarter in 2023. The Dublin-based company also provided an update on its DMT-related drugs that are currently undergoing clinical trials.

Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials

Psyched

Biotech

AGNPF

ATAI

CMND

CMPS

DRUG

ENVB

IXHL

LSDI

MNMD

OPTHF

PSIL

SILO

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna &amp; More

Financing

Legal

Management

MDXXF

TSLA

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta&#39;s Influence

GH Research PLC

In the latest chapter of Alabama&#8217;s medical cannabis rollout saga, local cannabis company <a href="https://www.benzinga.com/topic/alabama-always-llc">Alabama Always, LLC</a> has filed a lawsuit against the Alabama Medical Cannabis Commission (AMCC), seeking a partial summary judgment and a permanent injunction. <a href="https://www.alreporter.com/2024/09/18/new-amcc-lawsuit-chaos-delays-and-broken-rules-in-alabamas-cannabis-rollout/">According</a> to Alabama Political Reporter, the lawsuit accuses the AMCC of violating the Alabama Administrative Procedure Act (AAPA), citing numerous procedural failures that have derailed the state's medical cannabis program, leaving thousands of patients in limbo.
At the core of the legal battle are the Commission's <a href="https://www.benzinga.com/markets/cannabis/23/12/36115077/cannabis-licensing-saga-continues-in-alabama-troubled-marijuana-regulator-hit-with-new-lawsuit">controversial decisions on integrated license awards</a> and denials in 2023. Alabama Always argues that these decisions were not only flawed but illegal, claiming the AMCC bypassed mandatory contested case hearings and violated its own blind scoring rules.
<h3 class="wp-block-heading">Key Allegations Against The AMCC</h3>
Alabama Always alleges that the AMCC&#8217;s reliance on an "investigative hearing" process undermines transparency and due process. The company contends that the Commission's refusal to follow the AAPA and its insistence on continuing with its invalid hearing practices will only further delay the already troubled rollout of medical cannabis.
In addition to these claims, the lawsuit targets the AMCC's adoption of an "emergency rule" in October 2023, which the plaintiff says was implemented without the required public notice or comment. According to Alabama Always, the rule was designed to fast-track the licensing process at the expense of transparency and accountability.
Attorney Will Somerville, representing Alabama Always, emphasized the Commission's failure to comply with state law. &#8220;They have never explained why some people got licenses and some didn't. Most egregiously to me, they didn't explain how they thought some people could do the job of producing medical cannabis while others couldn't," Somerville said, urging the court to force the AMCC to start fresh and adhere to legal requirements.
<h3 class="wp-block-heading">Legal Delays Impact Patients And Businesses</h3>
The lawsuit isn&#8217;t just a bureaucratic battle; real lives are at stake. Patients in Alabama waiting for access to <a href="https://www.benzinga.com/topic/medical-cannabis">medical cannabis</a> continue to suffer as the Commission's administrative failures drag on. Observers have criticized the AMCC for prioritizing self-preservation over fixing the flawed process.
As the legal process unfolds, Judge James H. Anderson will determine whether Alabama Always's motion will reset the entire licensing process, or if the AMCC will continue its current practices, further entrenching uncertainty for the patients and businesses involved.
Cover image made with AI

Alabama Marijuana Company Sues Medical Cannabis Commission Over Licensing Chaos, Seeks Program Overhaul As Patients Remain In Limbo

KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>)&nbsp;announced today that KTJV, a KBR and Technip Energies joint venture, has been selected by Lake Charles&nbsp;LNG Export Company, a subsidiary of Energy Transfer LP, for its Lake Charles LNG transformation project.
Under the terms of the agreement, KTJV will provide high-end engineering, procurement, construction management, construction, commissioning, startup and other related services, subject to Lake Charles LNG's decision to issue a notice to proceed for the project.
The project would transform Energy Transfer's existing import facility into a world-class LNG export facility to meet the world's growing LNG and energy security demands. This conversion would include the delivery of three liquefaction trains and modifications to existing storage and dock facilities designed to enable the export of 16.45 metric tons per annum of LNG.

Contracts

KBR Announces KTJV, A KBR And Technip Energies Joint Venture, Has Been Selected By Lake Charles LNG Export Company, A Subsidiary Of Energy Transfer LP, For Its Lake Charles LNG Transformation Project

WIIM

MLKN

MillerKnoll shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 EPS guidance below estimates.

Guidance

SBGI

Sinclair Updates Q3 Political Advertising Revenue Guidance From $113M-$128M To $140M-$145M; Now Sees Q3 Local Media Advertising Revenue $425M-$438M, Up From Prior Expectation Of $401M-$428M

On Friday, September 13, Washington D.C. authorities shut down Green Cloud Shop, an unlicensed cannabis business, as part of a broader crackdown on illegal cannabis operations.
The Alcoholic Beverage and Cannabis Administration (ABCA), alongside the Metropolitan Police Department (MPD), <a href="https://abca.dc.gov/release/abca-shutters-illegally-operating-cannabis-business#gsc.tab=0">padlocked</a> the shop. The owner, a 49-year-old man, was arrested and charged with Possession with Intent to Distribute and Operating a Business After Certificate of Authority had been revoked.
This measure came in the context of an ongoing conflict with unregulated &#8220;gift economy&#8221; cannabis shops, which were tolerated in the past but are now being pushed to adapt to regulations, <a href="https://www.axios.com/local/washington-dc/2024/09/18/marijuana-dispensary-gifting-shops-crackdown">reported</a> Axios.
<h3 class="wp-block-heading">Say Goodbye To D.C.&#8217;s Cannabis Gifting Economy</h3>
Cannabis gifting shops in D.C. have long used a loophole by "gifting" marijuana when customers purchase other products. This allowed them to bypass laws against recreational cannabis sales, in the context of the tricky legal situation affecting Washington D.C. cannabis.
However, city officials are now stepping up enforcement. The more than 100 unlicensed shops that are currently operating are seen as a major threat to the legal medical cannabis market.
The crackdown comes after the D.C. Council green-lit an emergency bill to give city officials the authority to impose penalties on unlicensed cannabis stores <a href="https://www.benzinga.com/markets/cannabis/24/01/36597430/new-emergency-law-empowers-authorities-to-crack-down-on-cannabis-gifting-shops-in-d-c">earlier this year</a>. D.C. lawmakers, including progressive members, are backing this crackdown due to concerns about crime around all-cash businesses and the proximity of some shops to schools and daycare facilities.
<ul>
<li>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/03/37896144/washington-state-gov-signs-bill-eliminating-medical-marijuana-tax-iowa-to-add-25-excise-tax-on-h">Washington State Gov. Signs Bill Eliminating Medical Marijuana Tax, Iowa To Add 25% Excise Tax On Hemp &amp; More</a></li>
</ul>
<h3 class="wp-block-heading">The Latest Developments In D.C.</h3>
Green Cloud Shop's closure is part of a new wave of enforcement following the Medical Cannabis Conditional License and Unlicensed Establishment Closure Clarification Emergency Amendment Act of 2024. This law, enacted in July, grants the ABCA enhanced authority to close illegal businesses.
Green Cloud is the second illicit cannabis business closed by ABCA since the new law went into effect. 
Curiously, authorities reported padlocking the access to the store. This echoes New York&#8217;s <a href="https://www.benzinga.com/markets/cannabis/24/09/40910485/is-mayor-adams-crackdown-on-illegal-cannabis-working-nyc-council-weighs-in-after-1-000-store-clo">special operation</a> that cracked down on illicit cannabis during the first few months of the year.
In addition to the closures, the ABCA has issued 23 cease-and-desist orders and 79 warning letters to unlicensed cannabis businesses. Many shops, however, continue operating, with only a few being forced to shut down.
But still, property owners of illicit cannabis shops could face a $10,000 fine if they fail to comply with the ABCA's closure orders.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">The Struggle Of Legal D.C. Cannabis Dispensaries</h3>
The crackdown comes at a crucial time for D.C.'s legal <a href="https://www.benzinga.com/markets/cannabis/24/06/39262441/washington-provides-tax-break-for-medical-cannabis-users-but-is-it-enough">medical cannabis </a>market, which has been <a href="https://www.benzinga.com/markets/cannabis/24/07/39937544/medical-marijuana-market-in-d-c-at-risk-of-perishing-affected-business-owner-explains">struggling to compete</a> with unlicensed operators. 
Adding to the pressure, D.C. dispensaries face stiff competition from Maryland's legal recreational market, where prices are often lower. Since January 2024, D.C.'s legal market has been in a steep decline, selling less than 400 pounds of flower per month. 
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/06/39262441/washington-provides-tax-break-for-medical-cannabis-users-but-is-it-enough">Washington Provides Tax Break For Medical Cannabis Users, But Is It Enough?</a></li>
</ul>
Cover: Benzinga edit based on Washarapol D BinYo Jundang and Anna Lowe via Pixels

Government

Regulations

Politics

Markets

D.C. Continues Crackdown On Cannabis Gifting Shops: One Arrested, Store Padlocked, Although Many More Remain Open

Alternus Clean Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>) ("Alternus" or the "Company"), a leading utility-scale transatlantic, clean energy independent power producer (IPP), has terminated its MIPSA with C2 Taiyo Fund I, LLP to acquire approximately 80MWp solar installations across 8 U.S. states, originally announced on May 1, 2024, due to seller's failure to meet the required closing conditions and fundamental changes in the portfolio of assets planned to be acquired.

ALCE

Alternus Clean Energy Has Terminated Its MIPSA With C2 Taiyo Fund I, LLP To Acquire ~80MWp Solar Installations Across 8 U.S. States, Originally Announced On May 1, 2024, Due To Seller's Failure To Meet The Required Closing Conditions And Fundamental Changes In The Portfolio Of Assets Planned To Be Acquired

Nike shares are trading higher after the company announced Elliot Hill will take over as the new President and CEO. John Donahoe will retire from his position.

TechnipFMC Awarded Two Subsea Contracts By Petrobras For Brazil's Pre-Salt Fields; First Contract Is Between $250M-$500M And Second Is Between $75M-$250M

GNFT

CORRECTION: Genfit H1 2024 Adj. EPS €0.53; Revenues And Other Income €61.199M

Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $562,711, and 5 were calls, valued at $259,716.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $100.0 for Moderna during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of 2,026.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $60.0 to $100.0 over the last 30 days.
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726777077_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.9</td>
<td>$24.35</td>
<td>$25.9</td>
<td>$90.00</td>
<td>$388.5K</td>
<td>1.9K</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$13.3</td>
<td>$13.25</td>
<td>$13.3</td>
<td>$70.00</td>
<td>$81.1K</td>
<td>108</td>
<td style="text-align: right;">123</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$31.0</td>
<td>$30.85</td>
<td>$31.0</td>
<td>$100.00</td>
<td>$65.1K</td>
<td>0</td>
<td style="text-align: right;">609</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.66</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$60.00</td>
<td>$59.3K</td>
<td>1.6K</td>
<td style="text-align: right;">233</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.55</td>
<td>$80.00</td>
<td>$58.5K</td>
<td>702</td>
<td style="text-align: right;">536</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Trading volume stands at 5,013,059, with MRNA's price down by -2.52%, positioned at $68.1.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 42 days.</li>
</ul>
<h3>What Analysts Are Saying About Moderna</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $82.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Sector Perform, setting a price target of $75. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Moderna, which currently sits at a price target of $75. 
&#x2A; An analyst from Jefferies has revised its rating downward to Hold, adjusting the price target to $65. 
&#x2A; An analyst from HSBC upgraded its action to Hold with a price target of $82. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Moderna, targeting a price of $115. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

MRNA

Behind the Scenes of Moderna's Latest Options Trends

Offerings

KOPN

Kopin Corporation Announces Public Offering of Common Stock and Pre-Funded Warrants, Plans to Use Proceeds for Corporate Purposes and Potential Litigation Payments; Size Not Disclosed

Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) reported quarterly earnings of $0.57 per share. This is a 226.67 percent increase over losses of $(0.45) per share from the same period last year. The company reported $63.49 million in sales this quarter. This is a 281.83 percent increase over sales of $16.63 million the same period last year.

Genfit H1 EPS $0.57 Up From $(0.45) YoY, Sales $63.49M Up From $16.63M YoY (Converted To USD)

TIGO

Millicom International Cellular Appoints Maxime Lombardini As Interim Chair Of The Board

Nike Says Elliott Hill To Join Nike Board And Executive Committee

Cryptocurrency markets are trading 5.9% higher to $2.19 trillion as crypto short liquidations spiked to the highest level since Aug. 23.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$63,485.74</td>
<td>+5.3%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,467.60</td>
<td>+6.6%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$143.74</td>
<td>+10.8%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1062</td>
<td>+5%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.0000142</td>
<td>+6.3%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows a 1% drop in large transaction volume and a 5.7% decline in daily active addresses. However, exchanges netflows narrowed by 278.4%. With Bitcoin prices racing beyond the $61,000 mark, 88% of Bitcoin holders are in profit, while 12% are at breakeven.</li>
<li>Coinglass data shows 61,634 traders liquidated in the past 24 hours for $190.39 million, with short liquidations coming in at $117.6 million, the highest level since Aug. 23.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40943186/cybercriminals-busted-for-243m-crypto-heist-they-spent-hundreds-of-thousands-in-night-club">Cybercriminals Busted For $243M Crypto Heist: They Spent Hundreds Of Thousands In Night Clubs And On Luxury Gifts</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40942924/whats-going-on-with-coinbase-stock">What&#8217;s Going On With Coinbase Stock?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40944865/jade-city-to-democratize-access-to-50b-jade-market-with-tokenization-platform">Jade City To Democratize Access To $50B Jade Market With Tokenization Platform</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Popcat (SOL) (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">POPCAT</a>)</td>
<td>$0.8976</td>
<td>+28.2%</td>
</tr>
<tr>
<td>Sei (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SEI</a>)</td>
<td>$0.3344</td>
<td>+19.9%</td>
</tr>
<tr>
<td>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)</td>
<td>$1.77</td>
<td>+18.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices chasing the $63,000 mark, Cold Blooded Shiller predicts that if this move breaks to the upside, &#8220;expect this area to be a sweep with a fast response back.&#8221; He suggests keeping note of the $61,500 level.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If we get the LTF <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> correction I think the reaction around $61.5k will be important. If this move is going to break HTF structure to the upside I&#39;d expect this area to be a sweep with a fast response back. (The good ol&#39; V-reversal days) <a href="https://t.co/0nowzEJ8dL">pic.twitter.com/0nowzEJ8dL</a>
&mdash; Cold Blooded Shiller (@ColdBloodShill) <a href="https://twitter.com/ColdBloodShill/status/1836847538164363288?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">Crypto trader Scient <a href="https://x.com/Crypto_Scient/status/1836849315878256780">states</a> that this is that part of cycle where Bitcoin cools off, &#8220;does a bit of correction and altcoins take the lead.&#8221; However, after Bitcoin&#8217;s consolidation, it takes the lead again, makes the next leg higher and altcoins slow down. </figcaption></figure>
Stockmoney Lizards marks this price movement as the beginning of the &#8220;final cycle pump&#8221; and expects the cycle top around September to October 2025 between $200,000 and $260,000.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a>: The Final Cycle Pump Begins We are entering what could be the final pump of this Bitcoin cycle. The cycle top is expected around September to October 2025. My personal price target for Bitcoin is between $200,000 and $260,000. Legend: Here, you can see the last three… <a href="https://t.co/f7BTzM8YyM">pic.twitter.com/f7BTzM8YyM</a>
&mdash; Stockmoney Lizards (@StockmoneyL) <a href="https://twitter.com/StockmoneyL/status/1836835839340597600?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40932192/trump-pays-up-for-smash-burgers-and-diet-cokes-with-bitcoin-during-new-york-campaign-halt-">Trump Pays Up For Smash Burgers And Diet Cokes With Bitcoin During New York Campaign Halt — Move Hailed As &#8216;One Of The Most Historic Transactions&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$POPCAT

$SEI

$SHIB

$SOL

$WIF

Bitcoin, Ethereum, Dogecoin Surge: Has The 'Final Cycle Pump' Really Started?

Nike, Inc. Board Of Directors Announces Long-time Nike Veteran Elliott Hill To Return As President And Chief Executive Officer John Donahoe To Retire From Nike

NWTN

NWTN Suspends Rabdan Vehicle Production Following UAE Authority's Directive, Rebadges 320 Vehicles, Expects $17M Inventory Impairment, Reduces Workforce by 57%, and Explores New Partnerships Amid Challenges

AENT

Alliance Entertainment shares are trading higher after the company reported better-than-expected full-year 2024 adjusted EPS results.

Simon Property Group Amended, Restated And Extended $3.5B Revolving Credit Facility

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial &nbsp;
Results to be presented at the American Heart Association (AHA) Scientific Sessions in November 2024
Phase 1b single dose hemodynamic proof-of-concept clinical trial in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) escalated to the highest dose of TX45 (3 mg/kg) based on favorable tolerability profile observed at lower doses, with topline trial results expected in the second quarter of 2025
WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced favorable Phase 1a topline data for its lead asset TX45, a long-acting, potentially best-in-class relaxin. TX45 is being developed for the treatment of Group 2 PH-HFpEF.

General

TECX

Tectonic Therapeutic Announces Phase 1a Safety, Tolerability And PK/PD Results For Lead Program TX45; TX45 Was Well-tolerated With No Observed Immunogenicity, And Demonstrated A Favorable PK/PD Relationship Which Was Used To Identify Doses For The Phase 2 Clinical Trial

Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on GH Research (GHRS – Research Report). The associated price target is $39...

Buy Rating Affirmed for GH Research Amid Anticipated Clinical Advances and Strong Leadership

GH Research (GHRS) has released an update. GH Research PLC, an Ireland-based company, has announced its participation in the upcoming Morgan Stanle...

GH Research to Connect at Global Healthcare Conference

Sumant Kulkarni, an analyst from Canaccord Genuity, maintained the Buy rating on GH Research (GHRS – Research Report). The associated price target ...

Maintaining Buy Rating on GH Research Amidst CEO Transition and Promising GH001 Trials

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on GH Research (GHRS – Research Report) today and set a price target of $40.00. Pa...

Buy Rating Affirmed on GH Research Amid Anticipated Phase 2 Advances and Strong Market Potential

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.

Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August

TD Cowen analyst Ritu Baral has maintained their bullish stance on GHRS stock, giving a Buy rating yesterday. I'm sorry, but I cannot provide the r...

Understanding Incomplete Data: A Call for Comprehensive Analyst Reports

GH Research (GHRS) has released an update. GH Research PLC, an Ireland-based company, has announced its participation in the upcoming H.C. Wainwrig...

GH Research to Engage at Global Investment Conference

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are having growing pains.

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week

GH Research (GHRS) has released an update. GH Research PLC has announced their participation in the upcoming Cantor Global Healthcare Conference, s...

GH Research Engages Investors at Healthcare Conference

Press Releases

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

GH Research Reports Third Quarter Financial Results and Provides Business Updates

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Health Care

GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

GH Research

GH Research (GHRS) Forecast

GH Research (NASDAQ:GHRS) Stock, Quote.Headers.trade-ideas